Speciality: Pediatrics
Description:
A warm welcome to all the medical professionals in this interesting session on The game changing DTP Combination Vaccine evolution to improve VCR
The DTP combination vaccine, which protects against diphtheria, tetanus, and pertussis, has undergone significant evolution over the years, becoming a game-changer in global immunization efforts. The original whole-cell pertussis vaccine (DTPw), while effective, was associated with higher rates of side effects such as fever and injection site reactions. This led to the development of the acellular pertussis vaccine (DTPa), which contains purified components of the pertussis bacterium, resulting in fewer side effects and improved acceptance among parents and healthcare providers.
The evolution of the DTP vaccine has had a profound impact on Vaccine Coverage Rates (VCR). The shift from DTPw to DTPa, coupled with combination vaccines that include protection against additional diseases like Haemophilus influenzae type b (Hib) and hepatitis B, has streamlined immunization schedules and reduced the number of injections required. This convenience has improved VCR, particularly in countries where access to healthcare can be challenging. The introduction of hexavalent vaccines, which combine DTPa with vaccines for Hib, hepatitis B, and polio, represents the latest advancement, further simplifying immunization programs and enhancing global efforts to protect children against multiple life-threatening diseases.
Therefore, get an overall knowledge of the game changing DTP combination vaccine evolution to improve VCR
1.
Physician Fights Insurer to Cover Her Baby's Brain Cancer Treatment
2.
A small rise in cancer was observed following the 1986 Chernobyl accident.
3.
First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.
4.
New research uncovers link between cancer pathway and blood-retina barrier function
5.
Standardized criteria for amino acid PET imaging could improve diagnosis and treatment of brain metastases
1.
Bispecific Antibodies in DLBCL & Myeloma: Clinical Insights for Physicians
2.
Survivorship Planning Beyond Active Cancer Care
3.
Understanding Blood Dyscrasia: Symptoms, Causes and Treatment Options
4.
Integrated Models in Hematology for Specialists
5.
Matrix Metalloproteinases in Stroke: Broad vs. Selective Inhibition Strategies
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
5.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation